Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. [Dataset]

Abstract

Effective management of axial spondyloarthritis (axSpA)-related fatigue is a major unmet clinical need. Anti-TNF therapy may reduce fatigue levels, although any effect has yet to be definitively quantified and predictors of any such improvements are unknown. Anti-TNF therapy results in a significant but modest reduction in fatigue amongst axSpA patients, with those reporting poor sleep quality most likely to report improvement. Effective management will likely require additional approaches. The accompanying file contains supplementary tables and figure.

Citation

SHIM, J., DEAN, L.E., KARABAYAS, M., JONES, G.T., MACFARLANE, G.J. and BASU, N. 2020. Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. [Dataset]. Rheumatology [online], 59(11), pages 3408-3414. Available from: https://academic.oup.com/rheumatology/article/59/11/3408/5825444#209624591

• Acceptance Date: Feb 24, 2020
• Online Publication Date: Apr 26, 2020
• Publication Date: Nov 30, 2020
• Deposit Date: Oct 19, 2021
• Publicly Available Date: Oct 19, 2021
• Publisher: Oxford University Press
• DOI: https://doi.org/10.1093/rheumatology/keaa132
• Keywords: atigue; Anti-tumour necrosis factor; Axial spondylarthritis; Sleep; Registry; Meta-analysis
• Public URL: https://rgu-repository.worktribe.com/output/1499795
• Related Public URLs: https://rgu-repository.worktribe.com/output/1447196
• Type of Data: Supplementary tables and figure.
• Collection Date: Dec 31, 2017
• Collection Method: The British Society of Rheumatology Register in Axial Spondyloarthritis (BSRBR-AS) prospectively recruited axSpA patients across the UK. Changes in fatigue levels (measured using the Chalder Fatigue Scale) >1 year were compared between those starting anti-TNF therapy at the time of recruitment and those not. Differences between treatment groups were adjusted using propensity score matching. Results were meta-analysed with the extant literature to calculate pooled estimates. Then, among those BSRBR-AS anti-TNF commencers with clinically relevant fatigue, baseline predictors of response were investigated. The full description of Methods is available from the main full text article (https://doi.org/10.1093/rheumatology/keaa132).